Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
ELND005 in Patients With Mild to Moderate Alzheimer's Disease
NCT00568776 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to evaluate the dose-related safety and efficacy of multiple oral dosages of ELND005 as treatment for Alzheimer's disease (AD).
Conditions Studied
Interventions
- DRUG Placebo Control
- DRUG ELND005
Study Locations (20)
Florida
- Brain Matters Research, Inc. — Delray Beach
- Sunrise Clinical Research, Inc — Hollywood
- Miami Jewish Home and Hospital For The Aged — Miami
- Avision Research Associates, LLC — Miami
- Compass Research, LLC — Orlando
- Roskamp Institute — Sarasota
- Neurology Clinical Research, Inc. — Sunrise
- University of South Florida Suncoast Alzheimer's and Gerontology Center — Tampa
- Premiere Research Institute — West Palm Beach
California
- Margolin Brain Institute — Fresno
- Collaborative NeuroScience Network, Inc. — Garden Grove
- UCLA Alzheimer's Disease Center, Dept. of Neurology — Los Angeles
- UC Irvine Medical Center — Orange
- UCSF Medical Center, Dept. of Neurology — San Francisco
Arizona
- Banner Alzheimer's Institute — Phoenix
- Sun Health Research Institute — Sun City
- University of Arizona, Health Sciences Center, Dept. of Neurology — Tucson
Connecticut
- Yale University School of Medicine, Alzheimer's Disease Research Unit — New Haven
District of Columbia
- Georgetown University Medical Center, Dept. of Neurology — Washington D.C.
Georgia
- Emory University, Dept. of Neurology — Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 353 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00568776
The ClinicalTrials.gov registry entry for NCT00568776 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 353 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OPKO Health, which has 5 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions — of which Placebo Control is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00568776 reports 20 study locations spanning 6 distinct geographic areas — top geographies include Florida, California, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00568776 about?
NCT00568776 is a clinical study titled "ELND005 in Patients With Mild to Moderate Alzheimer's Disease". The purpose of this study is to evaluate the dose-related safety and efficacy of multiple oral dosages of ELND005 as treatment for Alzheimer's disease (AD).
What is the current status of trial NCT00568776?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 353 participants. The study started on 2007-12. Estimated completion is 2010-05.
What conditions does trial NCT00568776 study?
This clinical trial studies the following conditions: Alzheimer Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00568776?
The interventions under investigation include: Placebo Control (DRUG), ELND005 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00568776?
This trial is sponsored by OPKO Health, which has 5 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00568776 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.